Latest news with #Pansoft
Yahoo
28-05-2025
- Business
- Yahoo
Global Value Stocks Trading At Estimated Discounts In May 2025
In May 2025, global markets are navigating a turbulent landscape marked by renewed tariff threats and volatility in the Treasury market, which have contributed to declines in major stock indexes. Amid these challenges, investors may find opportunities in undervalued stocks that offer potential value based on their fundamentals and current market conditions. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.19 CN¥28.32 49.9% Sanil Electric (KOSE:A062040) ₩66100.00 ₩130358.74 49.3% Laboratorios Farmaceuticos Rovi (BME:ROVI) €52.35 €104.47 49.9% Sahara International Petrochemical (SASE:2310) SAR18.80 SAR37.34 49.7% H.U. Group Holdings (TSE:4544) ¥3056.00 ¥6024.98 49.3% Dive (TSE:151A) ¥921.00 ¥1821.20 49.4% BalnibarbiLtd (TSE:3418) ¥1160.00 ¥2296.58 49.5% Cosmax (KOSE:A192820) ₩202500.00 ₩404786.42 50% J&T Global Express (SEHK:1519) HK$6.65 HK$13.21 49.7% Northern Data (DB:NB2) €25.02 €49.53 49.5% Click here to see the full list of 516 stocks from our Undervalued Global Stocks Based On Cash Flows screener. Let's uncover some gems from our specialized screener. Overview: Tsinghua Tongfang Co., Ltd. operates in digital information, civil nuclear technology, energy conservation and environmental protection, and technology and finance sectors with a market cap of CN¥24.02 billion. Operations: The company's revenue segments include digital information, civil nuclear technology, energy conservation and environmental protection, and technology and finance businesses. Estimated Discount To Fair Value: 44.4% Tsinghua Tongfang is trading at a significant discount, with its current price of CN¥7.23 well below the estimated fair value of CN¥13.01, indicating potential undervaluation based on cash flows. Despite recent financial challenges, including a net loss of CNY 287.6 million in Q1 2025, earnings are forecast to grow substantially at 93.8% annually over the next three years, outpacing both industry peers and the broader Chinese market growth rates. Our expertly prepared growth report on Tsinghua Tongfang implies its future financial outlook may be stronger than recent results. Take a closer look at Tsinghua Tongfang's balance sheet health here in our report. Overview: Jiangsu Shentong Valve Co., Ltd. is engaged in the research, development, production, and sale of special valves both in China and internationally, with a market cap of CN¥5.79 billion. Operations: The company generates revenue from the research, development, production, and sale of special valves within China and on an international scale. Estimated Discount To Fair Value: 14.3% Jiangsu Shentong Valve is trading at CN¥11.87, below its estimated fair value of CN¥13.85, suggesting it may be undervalued based on cash flows. The company reported Q1 2025 earnings with a net income increase to CN¥89.5 million from the previous year's CN¥83.69 million, and revenue growth outpacing the market at 20.4% annually. Analysts expect significant annual profit growth of 24.8%, supported by a reliable dividend payout and strong earnings forecasts relative to peers. According our earnings growth report, there's an indication that Jiangsu Shentong Valve might be ready to expand. Navigate through the intricacies of Jiangsu Shentong Valve with our comprehensive financial health report here. Overview: Daiichi Sankyo Company, Limited is a pharmaceutical manufacturer and seller operating in Japan, North America, Europe, and internationally with a market cap of ¥7.11 trillion. Operations: The company's pharmaceutical operation generates revenue of ¥1.89 trillion. Estimated Discount To Fair Value: 48.6% Daiichi Sankyo, trading at ¥3,945, is valued below its estimated fair value of ¥7,679.39 according to cash flow analysis. The company's earnings grew by 47.3% last year and are forecasted to grow annually by 12.88%. Despite a dividend yield of 1.98% not being well-covered by free cash flows, the company has initiated share buybacks worth ¥200 billion to enhance shareholder value amidst ongoing legal challenges and promising oncology developments like ENHERTU's clinical success. Our growth report here indicates Daiichi Sankyo Company may be poised for an improving outlook. Unlock comprehensive insights into our analysis of Daiichi Sankyo Company stock in this financial health report. Discover the full array of 516 Undervalued Global Stocks Based On Cash Flows right here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:600100 SZSE:002438 and TSE:4568. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Asian Value Stocks Priced Below Estimated Intrinsic Values
As global markets face volatility due to renewed tariff threats and shifting economic policies, investors are increasingly turning their attention to Asia, where opportunities for value investing remain robust. In this environment, identifying stocks priced below their estimated intrinsic values can be a strategic approach for those seeking potential long-term growth in the Asian market. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.23 CN¥28.32 49.8% Xiamen Amoytop Biotech (SHSE:688278) CN¥77.56 CN¥153.79 49.6% Fuji (TSE:6134) ¥2247.00 ¥4481.26 49.9% H.U. Group Holdings (TSE:4544) ¥3062.00 ¥6058.85 49.5% Shenzhen Yinghe Technology (SZSE:300457) CN¥17.28 CN¥34.50 49.9% Devsisters (KOSDAQ:A194480) ₩38500.00 ₩76148.72 49.4% TLB (KOSDAQ:A356860) ₩17600.00 ₩34842.86 49.5% Heartland Group Holdings (NZSE:HGH) NZ$0.80 NZ$1.58 49.3% BalnibarbiLtd (TSE:3418) ¥1162.00 ¥2310.67 49.7% J&T Global Express (SEHK:1519) HK$6.65 HK$13.21 49.7% Click here to see the full list of 307 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea, with a market cap of ₩4.66 trillion. Operations: PharmaResearch Co., Ltd. focuses on biopharmaceutical operations primarily within South Korea. Estimated Discount To Fair Value: 24.7% PharmaResearch is trading at approximately 24.7% below its estimated fair value of ₩596,088.91, with a current price of ₩449,000. The company's earnings are forecast to grow significantly at 25.85% annually over the next three years, outpacing the Korean market average of 20.5%. Revenue growth is also expected to be robust at 24.4% per year, surpassing the market's 7.4%, highlighting its potential as an undervalued cash flow opportunity in Asia. Our comprehensive growth report raises the possibility that PharmaResearch is poised for substantial financial growth. Take a closer look at PharmaResearch's balance sheet health here in our report. Overview: Hyosung Heavy Industries Corporation manufactures and sells heavy electrical equipment both in South Korea and internationally, with a market cap of ₩5.67 trillion. Operations: Hyosung Heavy Industries generates revenue primarily through the manufacturing and sale of heavy electrical equipment domestically and abroad. Estimated Discount To Fair Value: 26.6% Hyosung Heavy Industries is trading at approximately 26.6% below its estimated fair value of ₩829,765.66, with a current price of ₩609,000. The company's earnings are projected to grow significantly at 21.94% annually over the next three years, exceeding the Korean market's growth rate of 20.5%. Although revenue growth is slower than desired at 9.8%, it still surpasses the market average of 7.4%, positioning it as an undervalued cash flow opportunity in Asia. Our growth report here indicates Hyosung Heavy Industries may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Hyosung Heavy Industries. Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩7.11 trillion. Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, amounting to ₩578 billion. Estimated Discount To Fair Value: 48.4% SK Biopharmaceuticals is trading at ₩90,800, significantly below its estimated fair value of ₩176,112.28, presenting a potential undervalued cash flow opportunity. Despite earnings growth forecasted at 18% annually—slightly below the Korean market's 20.5%—revenue is expected to increase by 22.8% per year, outpacing the market average of 7.4%. The company recently became profitable and anticipates high future returns on equity at 32.5%. Upon reviewing our latest growth report, SK Biopharmaceuticals' projected financial performance appears quite optimistic. Get an in-depth perspective on SK Biopharmaceuticals' balance sheet by reading our health report here. Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 307 companies by clicking here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 KOSE:A298040 and KOSE:A326030. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
28-05-2025
- Business
- Yahoo
Asian Value Stocks Priced Below Estimated Intrinsic Values
As global markets face volatility due to renewed tariff threats and shifting economic policies, investors are increasingly turning their attention to Asia, where opportunities for value investing remain robust. In this environment, identifying stocks priced below their estimated intrinsic values can be a strategic approach for those seeking potential long-term growth in the Asian market. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.23 CN¥28.32 49.8% Xiamen Amoytop Biotech (SHSE:688278) CN¥77.56 CN¥153.79 49.6% Fuji (TSE:6134) ¥2247.00 ¥4481.26 49.9% H.U. Group Holdings (TSE:4544) ¥3062.00 ¥6058.85 49.5% Shenzhen Yinghe Technology (SZSE:300457) CN¥17.28 CN¥34.50 49.9% Devsisters (KOSDAQ:A194480) ₩38500.00 ₩76148.72 49.4% TLB (KOSDAQ:A356860) ₩17600.00 ₩34842.86 49.5% Heartland Group Holdings (NZSE:HGH) NZ$0.80 NZ$1.58 49.3% BalnibarbiLtd (TSE:3418) ¥1162.00 ¥2310.67 49.7% J&T Global Express (SEHK:1519) HK$6.65 HK$13.21 49.7% Click here to see the full list of 307 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We'll examine a selection from our screener results. Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea, with a market cap of ₩4.66 trillion. Operations: PharmaResearch Co., Ltd. focuses on biopharmaceutical operations primarily within South Korea. Estimated Discount To Fair Value: 24.7% PharmaResearch is trading at approximately 24.7% below its estimated fair value of ₩596,088.91, with a current price of ₩449,000. The company's earnings are forecast to grow significantly at 25.85% annually over the next three years, outpacing the Korean market average of 20.5%. Revenue growth is also expected to be robust at 24.4% per year, surpassing the market's 7.4%, highlighting its potential as an undervalued cash flow opportunity in Asia. Our comprehensive growth report raises the possibility that PharmaResearch is poised for substantial financial growth. Take a closer look at PharmaResearch's balance sheet health here in our report. Overview: Hyosung Heavy Industries Corporation manufactures and sells heavy electrical equipment both in South Korea and internationally, with a market cap of ₩5.67 trillion. Operations: Hyosung Heavy Industries generates revenue primarily through the manufacturing and sale of heavy electrical equipment domestically and abroad. Estimated Discount To Fair Value: 26.6% Hyosung Heavy Industries is trading at approximately 26.6% below its estimated fair value of ₩829,765.66, with a current price of ₩609,000. The company's earnings are projected to grow significantly at 21.94% annually over the next three years, exceeding the Korean market's growth rate of 20.5%. Although revenue growth is slower than desired at 9.8%, it still surpasses the market average of 7.4%, positioning it as an undervalued cash flow opportunity in Asia. Our growth report here indicates Hyosung Heavy Industries may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Hyosung Heavy Industries. Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩7.11 trillion. Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, amounting to ₩578 billion. Estimated Discount To Fair Value: 48.4% SK Biopharmaceuticals is trading at ₩90,800, significantly below its estimated fair value of ₩176,112.28, presenting a potential undervalued cash flow opportunity. Despite earnings growth forecasted at 18% annually—slightly below the Korean market's 20.5%—revenue is expected to increase by 22.8% per year, outpacing the market average of 7.4%. The company recently became profitable and anticipates high future returns on equity at 32.5%. Upon reviewing our latest growth report, SK Biopharmaceuticals' projected financial performance appears quite optimistic. Get an in-depth perspective on SK Biopharmaceuticals' balance sheet by reading our health report here. Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 307 companies by clicking here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A214450 KOSE:A298040 and KOSE:A326030. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
27-05-2025
- Business
- Yahoo
Global Market's Trio Of Value Stocks Trading Below Estimated Worth
In the midst of recent global market volatility, spurred by tariff threats and fluctuating Treasury yields, investors are increasingly seeking opportunities to capitalize on stocks that may be trading below their intrinsic value. Identifying undervalued stocks can be particularly appealing in such an environment, as these equities often present potential for growth when market conditions stabilize or improve. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.23 CN¥28.33 49.8% Xiamen Amoytop Biotech (SHSE:688278) CN¥77.56 CN¥153.79 49.6% Fuji (TSE:6134) ¥2254.00 ¥4466.70 49.5% Shenzhen Yinghe Technology (SZSE:300457) CN¥17.28 CN¥34.49 49.9% adidas (XTRA:ADS) €218.70 €433.38 49.5% Clemondo Group (OM:CLEM) SEK10.70 SEK21.24 49.6% TLB (KOSDAQ:A356860) ₩17600.00 ₩34900.33 49.6% BalnibarbiLtd (TSE:3418) ¥1162.00 ¥2305.50 49.6% Nexstim (HLSE:NXTMH) €7.86 €15.69 49.9% Northern Data (DB:NB2) €24.78 €49.42 49.9% Click here to see the full list of 520 stocks from our Undervalued Global Stocks Based On Cash Flows screener. Let's dive into some prime choices out of the screener. Overview: Xiamen Amoytop Biotech Co., Ltd. focuses on the research, development, production, and sale of recombinant protein drugs in China with a market cap of CN¥30.42 billion. Operations: The company generates revenue primarily from its biologics segment, amounting to CN¥2.95 billion. Estimated Discount To Fair Value: 49.6% Xiamen Amoytop Biotech is trading at CN¥77.56, significantly below its estimated fair value of CN¥153.79, suggesting it may be undervalued based on cash flows. The company's earnings grew by 46.8% last year and are forecast to grow 28.5% annually, outpacing the market's growth rate. Recent transactions include a 5.7% stake acquisition by Tibet Trust Corporation for CNY 1.3 billion, highlighting investor interest amidst robust financial performance and growth prospects. In light of our recent growth report, it seems possible that Xiamen Amoytop Biotech's financial performance will exceed current levels. Take a closer look at Xiamen Amoytop Biotech's balance sheet health here in our report. Overview: Visional, Inc., along with its subsidiaries, offers human resources platform solutions in Japan and has a market cap of approximately ¥364.20 billion. Operations: The company's revenue is primarily derived from its HR Tech segment, which generated ¥69.50 billion, and its Incubation segment, contributing ¥2.10 billion. Estimated Discount To Fair Value: 43.7% Visional is trading at ¥9,211, considerably below its estimated fair value of ¥16,356.88, indicating potential undervaluation based on cash flows. Earnings are projected to grow at 14.7% annually, surpassing the JP market's growth rate of 7.6%. Revenue is expected to increase by 12.3% per year, also outpacing market averages. The company's return on equity is forecasted to reach a high level of 22.8% within three years, enhancing its investment appeal. Upon reviewing our latest growth report, Visional's projected financial performance appears quite optimistic. Dive into the specifics of Visional here with our thorough financial health report. Overview: KOSÉ Corporation is a company that manufactures and sells cosmetics and cosmetology products both in Japan and internationally, with a market cap of ¥313.40 billion. Operations: The company's revenue is primarily derived from its Cosmetics Business, which accounts for ¥256.70 billion, followed by Cosmetaries at ¥64.72 billion. Estimated Discount To Fair Value: 38.5% KOSÉ is trading at ¥5,566, significantly below its estimated fair value of ¥9,055.82. This undervaluation is highlighted by a forecasted annual earnings growth rate of 20.3%, outpacing the broader JP market's 7.6%. However, profit margins have decreased to 1.8% from last year's 4.7%, and the dividend yield of 2.52% isn't well covered by earnings or cash flows, presenting some challenges despite its attractive valuation based on cash flows. The analysis detailed in our KOSÉ growth report hints at robust future financial performance. Get an in-depth perspective on KOSÉ's balance sheet by reading our health report here. Click this link to deep-dive into the 520 companies within our Undervalued Global Stocks Based On Cash Flows screener. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688278 TSE:4194 and TSE:4922. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Asian Market Value Stock Picks For Potential Growth
As global markets face volatility and uncertainty, particularly with renewed tariff threats and fluctuating bond yields, investors are increasingly looking towards Asia for potential opportunities. In such a climate, identifying undervalued stocks that have strong fundamentals can be crucial for those seeking to capitalize on potential growth in the region's diverse economies. Name Current Price Fair Value (Est) Discount (Est) Pansoft (SZSE:300996) CN¥14.42 CN¥28.31 49.1% Darbond Technology (SHSE:688035) CN¥38.89 CN¥76.99 49.5% H.U. Group Holdings (TSE:4544) ¥3056.00 ¥6057.10 49.5% Polaris Holdings (TSE:3010) ¥222.00 ¥440.49 49.6% Brangista (TSE:6176) ¥595.00 ¥1177.43 49.5% Kanto Denka Kogyo (TSE:4047) ¥835.00 ¥1646.30 49.3% Devsisters (KOSDAQ:A194480) ₩38800.00 ₩76155.13 49.1% Heartland Group Holdings (NZSE:HGH) NZ$0.79 NZ$1.58 50% Dive (TSE:151A) ¥920.00 ¥1821.73 49.5% TLB (KOSDAQ:A356860) ₩17760.00 ₩34911.45 49.1% Click here to see the full list of 303 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Soosan Industries Co., Ltd. specializes in power plant construction and maintenance services in South Korea, with a market cap of ₩377.19 billion. Operations: The company's revenue segments include solar power, generating ₩11.25 billion, and power plant maintenance, contributing ₩305.92 billion. Estimated Discount To Fair Value: 18.7% Soosan Industries is trading at ₩26,800, below its estimated fair value of ₩32,974.42. Despite not being significantly undervalued by discounted cash flow analysis standards, the stock offers potential with earnings expected to grow significantly at 27.88% annually over the next three years. While revenue growth is projected at 8% per year—faster than the Korean market average—its return on equity remains forecasted to be relatively low at 11.5%. Our earnings growth report unveils the potential for significant increases in Soosan Industries' future results. Dive into the specifics of Soosan Industries here with our thorough financial health report. Overview: Kunshan Kinglai Hygienic Materials Co., Ltd. (SZSE:300260) operates in the hygienic materials industry and has a market cap of CN¥13.98 billion. Operations: Kunshan Kinglai Hygienic Materials Co., Ltd. generates its revenue from various segments within the hygienic materials industry, contributing to its market presence with a capitalization of CN¥13.98 billion. Estimated Discount To Fair Value: 40.4% Kunshan Kinglai Hygienic Materials is trading at CNY 34.46, significantly below its estimated fair value of CNY 57.85, suggesting undervaluation based on discounted cash flow analysis. Despite recent earnings declines, the company's revenue and earnings are forecast to grow substantially at 24.2% and 46.71% annually, respectively—outpacing the broader Chinese market growth rates. However, investors should note its high debt levels and recent share price volatility as potential risks. Upon reviewing our latest growth report, Kunshan Kinglai Hygienic MaterialsLtd's projected financial performance appears quite optimistic. Get an in-depth perspective on Kunshan Kinglai Hygienic MaterialsLtd's balance sheet by reading our health report here. Overview: KATITAS CO., Ltd. specializes in surveying, purchasing, refurbishing, remodeling, and selling used homes to individuals and families in Japan, with a market cap of ¥168.51 billion. Operations: The company's revenue is primarily generated from its House for Resale Reproduction Business, amounting to ¥129.54 billion. Estimated Discount To Fair Value: 37.5% KATITAS is trading at ¥2,155, significantly below its estimated fair value of ¥3,450.21, highlighting its undervaluation based on cash flows. The company's revenue and earnings are forecast to grow at 8.1% and 9.17% per year respectively, outpacing the Japanese market growth rates. However, the dividend yield of 3.25% is not well covered by free cash flows despite recent dividend increases and strong future earnings guidance indicating robust financial health ahead. In light of our recent growth report, it seems possible that KATITAS' financial performance will exceed current levels. Click to explore a detailed breakdown of our findings in KATITAS' balance sheet health report. Gain an insight into the universe of 303 Undervalued Asian Stocks Based On Cash Flows by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A126720 SZSE:300260 and TSE:8919. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
